|
| |
BioPortfolio's Approved Drugs DatabaseVaprisolConivaptan HydrochlorideDownload PDF containing detailed information.
Press Releases About Vaprisol:
|
 |
| Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia |
1st April, 2009 |
Astellas Pharma US, Inc. |
Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation
DEERFIELD, Ill., April 1 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability
|
| ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia |
27th October, 2008 |
ReachMD XM 157, Astellas Pharma US, Inc. |
CHICAGO, Oct. 27 /PRNewswire/ -- ReachMD XM 157 announces a new "Medical
Industry Feature of the Week" highlighting a vasopressin receptor antagonist
and its effects on management of
|
| FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia |
22nd October, 2008 |
Astellas Pharma US, Inc. |
DEERFIELD, Ill., Oct. 22 /PRNewswire/ -- Astellas Pharma US, Inc. today
announced that the U.S. Food and Drug Administration (FDA) has approved a new
premixed formulation of Vaprisol: Vaprisol(R)
|
This page has been viewed 28 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Vaprisol across BioPortfolio, or for Vaprisol Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|